You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
McKesson
Dow
Express Scripts

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABLAVAR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ablavar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00375830 Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases Completed Stanford University Phase 2 2006-01-01 This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
NCT01135316 Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Completed Lantheus Medical Imaging N/A 2009-10-01 Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
NCT01165892 Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) Completed Lantheus Medical Imaging N/A 2011-07-01 The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
NCT01165892 Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) Completed Washington University School of Medicine N/A 2011-07-01 The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ablavar

Condition Name

Condition Name for Ablavar
Intervention Trials
Neoplasms Staging 1
Myocardial Ischemia 1
Rectal Neoplasms 1
Magnetic Resonance Imaging 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ablavar
Intervention Trials
Myocardial Ischemia 1
Kidney Diseases 1
Ischemia 1
Heart Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ablavar

Trials by Country

Trials by Country for Ablavar
Location Trials
United States 6
Netherlands 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ablavar
Location Trials
North Carolina 2
California 2
Illinois 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ablavar

Clinical Trial Phase

Clinical Trial Phase for Ablavar
Clinical Trial Phase Trials
Phase 4 2
Phase 2 2
N/A 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ablavar
Clinical Trial Phase Trials
Completed 5
Terminated 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ablavar

Sponsor Name

Sponsor Name for Ablavar
Sponsor Trials
Lantheus Medical Imaging 3
Maastricht University Medical Center 3
Paul Finn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ablavar
Sponsor Trials
Other 9
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
Merck
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.